LEIDEN, NETHERLANDS--(Marketwire - December 08, 2008) - Dutch biopharmaceutical company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX), today announced that the Chinese Authorities have released Hepavax-Gene® for registration and quality control in China.
